Q4 FY2024 · ended Dec 31, 2024 · Revenue $0 · Filed Feb 19, 2026
Spyre Therapeutics, Inc. (SYRE) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$0
Net income
$-96.12M
-759.5% vs year-ago quarter
Operating cash flow
$-77.50M
-108.8% vs year-ago quarter
Free cash flow
—
EPS
$-0.74
Dividend per share
None
Shares outstanding
94.97M
+22.4% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SYRE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1636282
- Former names
- Aeglea BioTherapeutics, Inc. (until Nov 24, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$105.7M | -$41.6M | -$45.6M | -$57.2M | -$56.9M |
| Net income | -$96.1M | -$36.2M | -$69.0M | -$62.5M | -$11.2M |
| Diluted EPS | — | — | -$0.74 | — | — |
| Operating cash flow | -$77.5M | -$69.9M | -$57.4M | -$44.6M | -$37.1M |
| Total assets | $1.1B | $1.2B | $764.0M | $777.8M | $504.6M |
| Total liabilities | $48.2M | $71.9M | $93.1M | $62.5M | $49.5M |
| Stockholders' equity | $1.1B | $1.1B | $670.8M | $715.2M | $455.1M |
| Cash and investments | $1.1B | $1.1B | $741.5M | $756.5M | $486.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 7, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 25, 2026 | Aug 25, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
All 823 Spyre Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.